StreetInsider.com News Articles

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 16:05:00 -0400

BRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 10, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the three new non-executive employees received options to purchase 287,500 shares of Annexon common stock. The options carry a ten-year

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 16:05:00 -0400

In the aggregate, the three new non-executive employees received options to purchase 287,500 shares of Annexon common stock. The options carry a ten-year

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 16:05:00 -0400

In the aggregate, the three new non-executive employees received options to purchase 287,500 shares of Annexon common stock. The options carry a ten-year

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 16:05:00 -0400

In the aggregate, the three new non-executive employees received options to purchase 287,500 shares of Annexon common stock. The options carry a ten-year

Form 144 Annexon, Inc. Filed by: WIGGANS THOMAS G

Thu, 13 Aug 2026 15:35:00 -0400

si-local-file:///var/storage/secattach/20260813/26920312.html

Form 144 Annexon, Inc. Filed by: WIGGANS THOMAS G

Thu, 13 Aug 2026 15:35:00 -0400

si-local-file:///var/storage/secattach/20260813/26920312.html

Citizens Upgrades Annexon Biosciences (ANNX) to Market Perform

Thu, 13 Aug 2026 02:45:56 -0400

Citizens analyst Jonathan Wolleben upgraded Annexon Biosciences (NASDAQ: ANNX) from Market Underperform to Market Perform.

The analyst comments: “Adding vision preservation at month 24 as an independent, dual primary endpoint gives vonaprument a better opportunity to work in the Phase 3 ARCHER II trial; we are upgrading Annexon to Market Perform from Market Underperform based on our risk-adjusted, DCF-derived price target, and we view shares as fairly valued at these levels.

We continue to think vonaprument is unlikely to hit at the 15- month endpoint in 4Q26, but we think the downside on that miss is now more limited, with an opportunity

Citizens Upgrades Annexon Biosciences (ANNX) to Market Perform

Thu, 13 Aug 2026 02:45:56 -0400

Citizens analyst Jonathan Wolleben upgraded Annexon Biosciences (NASDAQ: ANNX) from Market Underperform to Market Perform.

We continue to think vonaprument is unlikely to hit at the 15- month endpoint in 4Q26, but we think the downside on that miss is now more limited, with an opportunity

Form 4 Annexon, Inc. For: Aug 10 Filed by: Blumenkranz Mark S.

Wed, 12 Aug 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260812/26914610.html

Form 4 Annexon, Inc. For: Aug 10 Filed by: Blumenkranz Mark S.

Wed, 12 Aug 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260812/26914610.html

Form 3 Annexon, Inc. For: Aug 10 Filed by: Blumenkranz Mark S.

Wed, 12 Aug 2026 18:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26914606.html

Form 3 Annexon, Inc. For: Aug 10 Filed by: Blumenkranz Mark S.

Wed, 12 Aug 2026 18:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26914606.html

Form 10-Q Annexon, Inc. For: Jun 30

Wed, 12 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260812/26912562.html

Form 10-Q Annexon, Inc. For: Jun 30

Wed, 12 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260812/26912562.html

Form 8-K Annexon, Inc. For: Aug 12

Wed, 12 Aug 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260812/26908497.html

Form 8-K Annexon, Inc. For: Aug 12

Wed, 12 Aug 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260812/26908497.html

Annexon, Inc. (ANNX) Misses Q2 EPS by 4c

Wed, 12 Aug 2026 06:20:10 -0400

Annexon, Inc. (NASDAQ: ANNX) reported Q2 EPS of ($0.28), $0.04 worse than the analyst estimate of ($0.24).

For earnings history and earnings-related data on Annexon, Inc. (ANNX) click here.

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Wed, 12 Aug 2026 06:05:00 -0400

Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026

Vonaprument Phase 3 GA Program Expanded with Month 15 / 24 Dual Primary Endpoint Strategy and Launch of Open-Label Extension Study; Month 15 Primary Endpoint on Track for Q4 2026

POC Data for ANX1502, a First-in-Kind Oral C1 Inhibitor for Autoimmune Disease, Expected in Fall 2026

$200 Million Credit Facility Strengthens Balance Sheet and Capabilities; Anticipated Runway Extended into 2028

Company to Host Business

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Wed, 12 Aug 2026 06:05:00 -0400

Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026

Vonaprument Phase 3 GA Program Expanded with Month 15 / 24 Dual Primary Endpoint Strategy and Launch of Open-Label Extension Study; Month 15 Primary Endpoint on Track for Q4 2026

POC Data for ANX1502, a First-in-Kind Oral C1 Inhibitor for Autoimmune Disease, Expected in Fall 2026

$200 Million Credit Facility Strengthens Balance Sheet and Capabilities; Anticipated Runway Extended into 2028

Company to Host Business

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Wed, 12 Aug 2026 06:05:00 -0400

Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026

Vonaprument Phase 3 GA Program Expanded with Month 15 / 24 Dual Primary Endpoint Strategy and Launch of Open-Label Extension Study; Month 15 Primary Endpoint on Track for Q4 2026

POC Data for ANX1502, a First-in-Kind Oral C1 Inhibitor for Autoimmune Disease, Expected in Fall 2026

$200 Million Credit Facility Strengthens Balance Sheet and Capabilities; Anticipated Runway Extended into 2028

Company to Host Business

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Wed, 12 Aug 2026 06:05:00 -0400

Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026

Vonaprument Phase 3 GA Program Expanded with Month 15 / 24 Dual Primary Endpoint Strategy and Launch of Open-Label Extension Study; Month 15 Primary Endpoint on Track for Q4 2026

POC Data for ANX1502, a First-in-Kind Oral C1 Inhibitor for Autoimmune Disease, Expected in Fall 2026

$200 Million Credit Facility Strengthens Balance Sheet and Capabilities; Anticipated Runway Extended into 2028

Company to Host Business

Annexon adds month 24 endpoint to phase 3 GA trial for vonaprument

Wed, 12 Aug 2026 06:00:16 -0400

Annexon, Inc. (Nasdaq: ANNX) announced the addition of a month 24 dual primary endpoint to its Phase 3 ARCHER II trial of vonaprument, a drug candidate for geographic atrophy (GA), a form of dry age-related macular degeneration. The company also launched an open-label extension (OLE) study of the treatment.

The ARCHER II trial previously had a single primary endpoint at month 15. With the dual primary endpoint structure, the trial can meet its primary objective at either month 15 or month 24, which are designated as independent efficacy timepoints. The primary measure is the proportion of patients experiencing confirmed best corrected

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

Wed, 12 Aug 2026 06:00:00 -0400

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of an open-label extension (OLE) study of vonaprument for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). With a dual primary endpoint strategy, ARCHER II can achieve success in protecting against vision

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

Wed, 12 Aug 2026 06:00:00 -0400

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of an open-label extension (OLE) study of vonaprument for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). With a dual primary endpoint strategy, ARCHER II can achieve success in protecting against vision

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

Wed, 12 Aug 2026 06:00:00 -0400

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of an open-label extension (OLE) study of vonaprument for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). With a dual primary endpoint strategy, ARCHER II can achieve success in protecting against vision